PureTech's Seaport Prices Upsized IPO Nasdaq: SPTX

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that its Founded Entity, Seaport Therapeutics, Inc. ("Seaport"), has announced the pricing of its upsized initial public offering of 14,160,000 shares of its common stock at a price to the public of $18.00 per share, at the top of the target range. The gross proceeds to Seaport from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $254.9 million. All of the shares are being offered by Seaport. In addition, Seaport has granted the underwriters a 30-day option to buy an additional 2,124,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker symbol "SPTX." The offering is expected to close on May 4, 2026 subject to the satisfaction of customary closing conditions.

Upon the closing of the offering, PureTech will hold 16,685,013 shares of Seaport common stock.

The full text of the announcement from Seaport is as follows:

Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, April 30, 2026 - Seaport Therapeutics, Inc., (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing neuropsychiatric medicines, today announced the pricing of its upsized initial public offering of 14,160,000 shares of its common stock at a price to the public of $18.00 per share, at the top of the target range. The gross proceeds to Seaport Therapeutics from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $254.9 million. All of the shares are being offered by Seaport Therapeutics. In addition, Seaport Therapeutics has granted the underwriters a 30-day option to buy an additional 2,124,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Global Select Market on May 1, 2026 under the ticker symbol "SPTX." The offering is expected to close on May 4, 2026 subject to the satisfaction of customary closing conditions.

Goldman Sachs & Co. LLC, J.P. Morgan, Leerink Partners, Citigroup, and Stifel are acting as joint book-running managers for the offering.

A registration statement relating to this offering has been filed with the Securities and Exchange Commission and was declared effective on April 30, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by emailing prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 866-803-9204, or by email at prospectus-eq_fi@jpmorganchase.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-800-831-9146; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by emailing syndprospectus@stifel.com.

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary GlyphTM platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families.